JETREA®: Up to 28,000 eyes treated and counting1
Starting in 2009, JETREA has been studied in over 1,400 eyes as part of the clinical trial program.
Since the FDA approval in October 2012, JETREA has received approval outside of the United States.
†Postmarketing eye exposure based on the total number of vials shipped by distributors. Due to buy-and-bill distribution of JETREA, this number is reflective of vials ordered and not necessarily vials used due to existing inventory that may be in retina specialists' freezers.
Patients who may benefit from JETREA treatment meet the following characteristics.
However, not all patients will respond.
Patients with ERM and/or an adhesion >1500 μm may be less likely to have VMA resolution.15,16
JETREA has been shown to be safe and effective in many symptomatic VMA patients.2,3,14
JETREA has been shown to be safe and effective in many symptomatic VMA patients.2,3,14LEARN MORE ABOUT HOW JETREA WORKS
Watch an in-depth overview of the aging eye and learn how JETREA works to help treat symptomatic VMA.
Watch a brief description of the aging eye and learn how JETREA works to help treat symptomatic VMA.
Post-hoc analysis of patient subgroups in "Oasis", a Two-Year Post-marketing Study, suggested different VMA resolution in 28 days possible in specific patient subgroups17*
*These data are from post hoc analyses and were not used for FDA approval.
†For the efficacy analysis, subjects were analyzed based on the randomization schedule according to the Intent-to-Treat principle.
|STUDY RESULTS: ADVERSE REACTIONS IN THE INJECTED EYE (% OF PATIENTS)1|
|JETREA (n=465)*||Vehicle (n=187)*|
|Days 0-7||Day 8−End of
|Days 0-7||Day 8−End of
|Reduced visual acuity||4.1||2.4||0||4.8|
The most common adverse reactions in the vehicle-controlled clinical studies were (incidence 5% – 20% listed in descending order of frequency): vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema.1
Less common adverse reactions observed in the studies at a frequency of 2% to <5% in patients treated with JETREA® included: macular edema, increased intraocular pressure, anterior chamber cell, photophobia, vitreous detachment, ocular discomfort, iritis, cataract, dry eye, metamorphopsia, conjunctival hyperemia, and retinal degeneration.1
*For the safety analysis, subjects were analyzed according to the actual treatment received. One subject received JETREA instead of the randomly assigned vehicle.Jetrea Dosing and Administration
Knowing how to dose and administer JETREA properly is important as it will impact safety and efficacy. Please view this short preparation and administration video featuring step-by-step instructions so you can become comfortable with using JETREA in your patients.
The JETREA Preparation and Administration Guide is provided in each JETREA shipment box and describes what is in the box, as well as the dosing and administration instructions.Learn What to Expect Post Injection
Because patient experiences with JETREA may vary, it is important to educate patients so they know what to expect.
JETREA has real-world global clinical experience in treating up to 28,000 eyes and counting.4
Some immediate side effects can include vision changes or eye pain. Other potential side effects may include3,8,9:
Most side effects occurred within the first week following injection and were transient and mild.14 Patients should report any side effects if they become severe or bothersome.